Pliant Therapeutics Inc
PLRX1.140USD
+0.050+4.59%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
70.05MMarket Cap
LossP/E TTM
More Details of Pliant Therapeutics Inc Company
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Pliant Therapeutics Inc Info
Ticker SymbolPLRX
Company namePliant Therapeutics Inc
IPO dateJun 03, 2020
CEOCoulie (Bernard J)
Number of employees171
Security typeOrdinary Share
Fiscal year-endJun 03
Address331 Oyster Point Boulevard
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16504816770
Websitehttps://pliantrx.com/
Ticker SymbolPLRX
IPO dateJun 03, 2020
CEOCoulie (Bernard J)
Company Executives of Pliant Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
616.26K
-89375.00%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-15713.00%
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Keith Cummings, M.D.
Dr. Keith Cummings, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Gayle Crowell
Ms. Gayle Crowell
Independent Director
Independent Director
--
--
Mr. Christopher Keenan
Mr. Christopher Keenan
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
616.26K
-89375.00%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-15713.00%
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Feb 4
Updated: Wed, Feb 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
9.77%
Woodline Partners LP
7.33%
Point72 Asset Management, L.P.
7.06%
Morgan Stanley & Co. LLC
5.69%
Citadel Advisors LLC
4.94%
Other
65.21%
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
9.77%
Woodline Partners LP
7.33%
Point72 Asset Management, L.P.
7.06%
Morgan Stanley & Co. LLC
5.69%
Citadel Advisors LLC
4.94%
Other
65.21%
Shareholder Types
Shareholders
Proportion
Hedge Fund
39.23%
Investment Advisor
22.12%
Investment Advisor/Hedge Fund
12.57%
Research Firm
12.08%
Individual Investor
2.40%
Family Office
0.87%
Venture Capital
0.76%
Private Equity
0.04%
Bank and Trust
0.02%
Other
9.92%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
358
52.26M
85.04%
-35.89M
2025Q3
356
52.49M
85.42%
-37.39M
2025Q2
374
62.63M
102.02%
-15.09M
2025Q1
390
63.45M
103.37%
-12.99M
2024Q4
392
71.13M
116.20%
-8.66M
2024Q3
388
69.61M
114.50%
-7.63M
2024Q2
375
69.93M
115.87%
-7.66M
2024Q1
371
73.36M
121.74%
-3.24M
2023Q4
362
70.03M
116.83%
-95.89K
2023Q3
356
64.13M
107.25%
-2.06M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tang Capital Management, LLC
6.00M
9.77%
+3.45K
+0.06%
Sep 30, 2025
Woodline Partners LP
4.50M
7.33%
+2.16M
+91.81%
Sep 30, 2025
Point72 Asset Management, L.P.
4.34M
7.06%
+4.34M
--
Sep 30, 2025
Morgan Stanley & Co. LLC
3.50M
5.69%
+1.50M
+75.33%
Sep 30, 2025
Citadel Advisors LLC
2.34M
3.81%
-16.43K
-0.70%
Sep 30, 2025
Blue Owl Capital Holdings LP
2.97M
4.83%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
2.78M
4.52%
-226.41K
-7.54%
Sep 30, 2025
Acadian Asset Management LLC
2.37M
3.86%
+739.13K
+45.33%
Sep 30, 2025
J.P. Morgan Securities LLC
2.13M
3.46%
+171.21K
+8.76%
Sep 30, 2025
Two Sigma Investments, LP
1.86M
3.02%
+1.11M
+148.96%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
DFA Dimensional US Core Equity Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Humankind US Stock ETF
0%
iShares Morningstar Small-Cap Value ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
DFA Dimensional US Core Equity Market ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Humankind US Stock ETF
Proportion0%
iShares Morningstar Small-Cap Value ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
